Macular Edema – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Macular Edema – Pipeline Review, H1 2020’, provides an overview of the Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Macular Edema

– The report reviews pipeline therapeutics for Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Macular Edema therapeutics and enlists all their major and minor projects

– The report assesses Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Macular Edema

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Macular Edema

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Anew Oncology Inc

AsclepiX Therapeutics Inc

Celon Pharma SA

Clearside BioMedical Inc

Coherus BioSciences Inc

F. Hoffmann-La Roche Ltd

Formycon AG

Lupin Ltd

Luye Pharma Group Ltd

Mabion SA

OMEICOS Therapeutics GmbH

PharmAbcine Inc

Polus Inc

Profarma

Sustained Nano Systems LLC

Taiwan Liposome Co Ltd

Targeted Therapy Technologies LLC

Tarsius Pharma Ltd

Xbrane Biopharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Macular Edema - Overview

Macular Edema - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Macular Edema - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macular Edema - Companies Involved in Therapeutics Development

Anew Oncology Inc

AsclepiX Therapeutics Inc

Celon Pharma SA

Clearside BioMedical Inc

Coherus BioSciences Inc

F. Hoffmann-La Roche Ltd

Formycon AG

Lupin Ltd

Luye Pharma Group Ltd

Mabion SA

OMEICOS Therapeutics GmbH

PharmAbcine Inc

Polus Inc

Profarma

Sustained Nano Systems LLC

Taiwan Liposome Co Ltd

Targeted Therapy Technologies LLC

Tarsius Pharma Ltd

Xbrane Biopharma AB

Macular Edema - Drug Profiles

ACX-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevacizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macular Edema - Dormant Projects

Macular Edema - Discontinued Products

Macular Edema - Product Development Milestones

Featured News & Press Releases

Apr 28, 2020: Clearside Biomedical revises NDA resubmission timeline and XIPERE commercial partnership with Bausch Health

Jan 28, 2020: Bausch Health and Clearside Biomedical announce publication of PIVOTAL phase 3 data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

Aug 22, 2019: Clearside Biomedical provides new drug application update for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)

Jul 31, 2019: Clearside Biomedical announces multiple oral presentations delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting

May 01, 2019: Clearside Biomedical presents on Triamcinolone at the American Uveitis Society Spring Meeting 2019

Apr 18, 2019: Clearside Biomedical announces presentations on its Suprachoroidal Space injection platform with Triamcinolone Acetonide at upcoming medical meetings

Feb 20, 2019: Clearside Biomedical receives notification of FDA acceptance of NDA filing for XIPERE (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection with PDUFA Date Set for October 19, 2019

Jan 20, 2019: Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE Exhibits Durability Following Second Dose

Dec 19, 2018: Clearside Biomedical submits New Drug Application for XIPERE for the treatment of Macular Edema associated with Uveitis

Oct 29, 2018: Presentation of additional analyses of Clearsides PEACHTREE clinical trial data further supports potential of XIPERE in treating uveitic macular edema

Oct 22, 2018: CLEARSIDE, XIPERE and PEACHTREE to be front and center at AAO 2018

Sep 18, 2018: Positive PEACHTREE Data to be Highlighted at EURETINA 2018

Sep 13, 2018: Data from Clearside Biomedical’s pivotal phase 3 PEACHTREE clinical trial in macular edema associated with non-infectious uveitis to be presented at the Retina Society 51st Annual Scientific Meeting

Sep 12, 2018: Single suprachoroidal steroid injection boosts visual acuity in patients with macular edema

Jul 16, 2018: Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Macular Edema, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Macular Edema – Pipeline by Anew Oncology Inc, H1 2020

Macular Edema – Pipeline by AsclepiX Therapeutics Inc, H1 2020

Macular Edema – Pipeline by Celon Pharma SA, H1 2020

Macular Edema – Pipeline by Clearside BioMedical Inc, H1 2020

Macular Edema – Pipeline by Coherus BioSciences Inc, H1 2020

Macular Edema – Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Macular Edema – Pipeline by Formycon AG, H1 2020

Macular Edema – Pipeline by Lupin Ltd, H1 2020

Macular Edema – Pipeline by Luye Pharma Group Ltd, H1 2020

Macular Edema – Pipeline by Mabion SA, H1 2020

Macular Edema – Pipeline by OMEICOS Therapeutics GmbH, H1 2020

Macular Edema – Pipeline by PharmAbcine Inc, H1 2020

Macular Edema – Pipeline by Polus Inc, H1 2020

Macular Edema – Pipeline by Profarma, H1 2020

Macular Edema – Pipeline by Sustained Nano Systems LLC, H1 2020

Macular Edema – Pipeline by Taiwan Liposome Co Ltd, H1 2020

Macular Edema – Pipeline by Targeted Therapy Technologies LLC, H1 2020

Macular Edema – Pipeline by Tarsius Pharma Ltd, H1 2020

Macular Edema – Pipeline by Xbrane Biopharma AB, H1 2020

Macular Edema – Dormant Projects, H1 2020

Macular Edema – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Macular Edema, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports